James Presses Congress to Label Xylazine a Controlled Substance, Eyes Supply Chain Crackdown

An animal tranquiliser is fuelling New York’s latest drug crisis—spotlighting gaping holes in America’s approach to synthetic drugs.

On a drizzly Kings County afternoon, emergency room doctors in East New York stabilised their third patient of the day—each unresponsive, each bearing ulcers to the bone. Their common thread: a gritty street cocktail laced with xylazine, known in local argot as “tranq.” Once reserved for sedating moose and mutts, the drug is now infiltrating New York City’s illicit opioid market with alarming speed.

It is this rapid spread that prompted Letitia James, New York’s Attorney General, to call on Congress this week to pass the Combating Illicit Xylazine Act. The bill, cosponsored by a bipartisan clutch of lawmakers, would—if enacted—designate xylazine as a federal controlled substance, subjecting distributors to the same regulatory regime that governs fentanyl and heroin.

Xylazine’s medical uses are undramatic; veterinarians rely on it to pacify large animals. For humans, the effect is wholly unlicensed: protracted sedation, respiratory depression, and gruesome, treatment-resistant skin necrosis. Unsurprisingly, illicit chemists and dealers sprinkle the drug into opioid supplies to increase potency at a puny cost. The combination has, according to New York City’s Department of Health, been detected in nearly a third of overdose deaths in 2023—a sharp increase from previous years.

If the statistics raise eyebrows, so too does the readiness of the city’s institutions to respond. Unlike opioids, xylazine is not neutralized by naloxone—the ubiquitous overdose-reversing spray—leaving users and first responders with little recourse. Outreach workers say the burden is not only clinical but economic: treating xylazine-linked wounds stretches city hospital budgets already under siege.

For law enforcement, the situation is doubly tricky. Because xylazine remains an unscheduled compound under federal law, dealers moving it run virtually no legal risk—at least relative to handling heroin or cocaine. Attorney General James’s entreaty to Congress, therefore, is less an act of pious rhetoric than a demand for basic prosecutorial tools. But policy alone will not solve the city’s growing dependence on Frankenstein pharmaceuticals.

The city stands at a crossroads. Drug trends in New York often offer a foretaste for the nation, and xylazine’s quick emergence here threatens to portend similar waves elsewhere. If Congress heeds Ms James’s plea, enforcement and supply may tighten, but substitutes—often of questionable chemistry—could well take its place. The tale is depressingly familiar to public-health veterans who watched the clampdown on prescription opioids foment a cascade into illicit fentanyl and, now, a proliferation of animal sedatives.

The social costs go well beyond the coroner’s ledger. As New Yorkers have learned, drugs like xylazine erode the already tenuous trust between public agencies and marginalised communities. Users, scarred by flesh-eating wounds and wary of authorities, vanish from care until crisis strikes. The city’s social safety net, always threadbare, frays further with each new compound that enters the fray.

Nationally, the picture looks as grim. The Centers for Disease Control and Prevention notes xylazine’s imprint on escalating overdose rates not only in traditional epicentres like Philadelphia and New York but even in heartland cities. International observers can only marvel at the peculiarity of a regulatory regime in which animal tranquilizers bypass scrutiny, only to be addressed reactively.

Globally, legislative fixes tend to lag street-level chemistry by years, if not decades. The United Kingdom, with its more centralised regulatory apparatus, faces fewer xylazine deaths—not for lack of supply, but because of more agile scheduling laws. America’s legislative process, by contrast, is perennially hamstrung by congressional inertia and the FDA’s labyrinthine procedures.

A call for smarter drug policy, not a new cat-and-mouse chase

Congressional scheduling of xylazine, while a welcome update, risks amounting to little more than a game of whack-a-mole. Dealers, ever adaptable, look set to reach for whatever unscheduled alternative presents itself next—alpha-pvp, isotonitazene, et al—rendering each victory pyrrhic. We would advise policymakers not to confuse regulatory theatre for meaningful harm reduction.

The real remedy may lie elsewhere. A data-forward approach—expanding drug-checking programmes, increasing the reach of medically assisted treatment, and investing in research—would better serve New Yorkers than simply adding compounds to a statutory blacklist. New York’s own pilot harm-reduction sites, while controversial, have demonstrated their utility in attracting users into services before catastrophe strikes.

There is a further, unsparing lesson here: America’s healthcare and regulatory systems are ill-equipped to manage the parade of chemical innovation that courses through its illicit markets. For all the resources spent on criminal interdiction, little goes to anticipate or preempt the next wave. The gap is less one of will than of outmoded institutional design.

Legislators in Albany and Washington would do well to remember that supply-side crackdowns rarely shift demand, barring the most draconian and socially costly measures. Instead, as New York’s history of drug use attests, each new fix will beget new fixes until underlying despair, poverty, and lack of access to care are addressed. Synthetic ingenuity in America’s drug trade is unlikely to abate; the response must be both swifter and smarter.

Attorney General James’s call is an overdue prompt for Congress to modernise regulation. But to turn the tide of xylazine-linked destruction, New York—and America—must also modernise its approach to public health and harm reduction. Prohibition alone is no panacea.

If New York is the nation’s laboratory, xylazine is its latest unsettling result. Policy that keeps one step ahead of the street chemists—or at least closes the gap—remains the city’s only viable prescription. ■